| Literature DB >> 32717940 |
Abstract
Hydroxycinnamic acids (HCAs) are important natural phenolic compounds present in high concentrations in fruits, vegetables, cereals, coffee, tea and wine. Many health beneficial effects have been acknowledged in food products rich in HCAs; however, food processing, dietary intake, bioaccessibility and pharmacokinetics have a high impact on HCAs to reach the target tissue in order to exert their biological activities. In particular, metabolism is of high importance since HCAs' metabolites could either lose the activity or be even more potent compared to the parent compounds. In this review, natural sources and pharmacokinetic properties of HCAs and their esters are presented and discussed. The main focus is on their metabolism along with biological activities and health benefits. Special emphasis is given on specific effects of HCAs' metabolites in comparison with their parent compounds.Entities:
Keywords: biological activities; diet; health effects; hydroxycinnamic acids; metabolites; natural compounds; pharmacokinetic properties; phenolic acids
Year: 2020 PMID: 32717940 PMCID: PMC7468728 DOI: 10.3390/nu12082190
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 5.717
Figure 1Structure of the main hydroxycinnamic acids (HCAs) and their esters as one of the major class of phenolic acids.
Figure 2Major metabolic reactions, enzymes and organs involved in HCAs metabolism; UGT, uridine-5′-diphosphate-glucuronosyltransferase; COMT, catechol-O-methyltransferase; SULT, sulfotransferase [62,63].
Figure 3Proposed metabolic pathways and metabolites of 5-O-caffeoylquinic, caffeic and ferulic acids; EST, esterase; CAI, caffeic acid isomerase; RED, reductase; COMT, catechol-O-methyltransferase; SULT, sulfotransferase; UGT, uridine-5′-diphosphate-glucuronosyltransferase; GLYAT, glycine-N-acyltransferase [52,70,71]. The main biological activities of selected metabolites are presented with appropriate symbols.
Figure 4Main metabolites of rosmarinic, chlorogenic, caffeic and ferulic acids that appeared after biotransformation by gut microflora [67,75,88,89]. The main biological activities of selected metabolites are presented with appropriate symbols.
Biological activities and underlying mechanism of major HCAs’ metabolites.
| Metabolite(s) | Biological Activity | Mechanism | Reference(s) |
|---|---|---|---|
| 3-(3,4-dihydroxyphenyl)lactic acid | antioxidant | radical scavenging ability (in vitro DPPH assay) | [ |
| caffeic acid-3-O- and 4-O-sulfate | antioxidant | ferric-reducing activity, reduction of the ABTS radical cation (in vitro assays) | [ |
| caffeic acid-3-O- and 4-O-glucuronide | antioxidant | ferric-reducing activity, reduction of the ABTS radical cation (in vitro assays) | [ |
| ferulic acid-4-O-glucuronide | antioxidant | potent activity in CuSO4-induced LDL autoxidation system (in vitro assay) | [ |
| caffeic acid-4-O-sulfate | antihipertensive | vasorelaxation of saphenous and femoral arteries and aortae in mice | [ |
| ferulic acid 1-O-acyl-glucuronide | antioxidant | ferric-reducing activity, reduction of the ABTS radical cation (in vitro assays) | [ |
| dihydrocaffeic acid | antioxidant | DPPH and lipid peroxyl radical scavenging ability, | [ |
| increased oxidative stability of lard (in vitro assays) | |||
| dose-dependent recovery of reduced glutathione and increased ROS levels in HepG2 cells, | [ | ||
| scavenging of intracellular ROS species in endothelial cells, | [ | ||
| enhanced nitric oxide synthase activity in a dose-related manner in EA.hy926 cells | |||
| prevention of oxidative stress and endothelial dysfunction in EA.hy926 cells | [ | ||
| anticancer | cytotoxicity for tested cancer cell lines (i.e., MCF-7, PC-3, and HCT-116) | [ | |
| chemoprotective - upregulation of GSTT2 and downregulation of COX-2 in human colon cells (LT97) | [ | ||
| anti-inflammatory | decreased secretion of pro-inflammatory cytokines TNF-α, IL-1β and IL-6 in human | [ | |
| prostaglandin E2 production inhibition in vitro in CD18-Co human colon fibroblast cells | [ | ||
| reduced number of abdominal constrictions, | |||
| higher weight tolerance in the paw-pressure test in rats | |||
| neuroprotective | prevention of neuronal apoptosis by reducing the ROS levels, enhanced redox activity, and reduced oxidative stress-elicited apoptosis in human neuroblastoma SH-SY5Y cells; | [ | |
| dose-dependent reduction of brain infarct volume, behavioral deficits, brain water content, and Evans Blue leakage in focal cerebral ischemia rat model; | [ | ||
| inhibition of expression and activation of MMP-2 and -9; | |||
| cardio-protective | Inhibition of in vitro platetet activation via decreased P-selectin expression | [ | |
| hepato-protective | prevention of cytotoxicity, macromolecular damage in | [ | |
| dihydroferulic acid | antioxidant and hepatoprotective | minor protective effects against cell cytotoxicity, lipid oxidation and glutathione depletion in HepG2 cells | [ |
| anti-inflammatory | prostaglandin E2 production inhibition in vitro in CD18-Co human colon fibroblast cells, reduced number of abdominal constrictions, enhanced weight tolerance in the paw-pressure test in rats; | [ | |
| inhibition of DSS-induced colitis, lipid peroxidation and DNA damage in colon mucosa, | |||
| downregulation of central pro-inflammatory cytokines (e.g., TNF-α, IL-1β, and IL-8) | |||
| cardio-protective | inhibition of in vitro platetet activation via decreased P-selectin expression | [ | |
| vanillic acid | antibacterial | inhibition of growth of methicillin-resistant and methicillin-susceptible | [ |
| anticancer | increased oxidative stress and apoptosis in non-small lung cancer NCI-H460 cell line | [ | |
| inhibition of breast and prostate cancer cell viability | [ | ||
| anti-inflammatory | reduced LPS-induced production of TNF-α and IL-6, | [ | |
| suppression of the elevated levels of COX-2, production of prostaglandin E(2) and NO in mouse peritoneal macrophages and activation of NF-κB and caspase-1; | |||
| reduction of CD40L-induced production of VCAM-1 production suppression of IL-6 production in oxidatively challenged HUVECs | [ | ||
| 3,4-dihydroxyphenylacetic acid | antioxidant | inhibition of lipid peroxidation in rat plasma | [ |
| anticancer | chemoprotective - upregulation of GSTT2 and downregulation of COX-2 in human colon cells (LT97) | [ | |
| antiproliferative activity in prostate and colon cancer cells | [ | ||
| anti-inflammatory | decreased secretion of pro-inflammatory cytokines TNF-α, IL-1 β and IL-6 in human; | [ | |
| blockage of prostaglandin E2 production in vitro in CD18-Co human colon fibroblast cells | [ | ||
| neuroprotective | prevention of neuronal apoptosis by reducing the ROS levels, enhanced redox activity, and reduced oxidative stress-elicited apoptosis in human neuroblastoma SH-SY5Y cells; | [ | |
| 3-(3-hydroxyphenyl)propionic acid | antioxidant | antioxidant activity in ORAC assay (in vitro assay) | [ |
| antihypertensive | NO-dependent effects, peripheral activity on vascular beds in rats | [ | |
| 4-hydroxyphenylacetic acid | antioxidant | radical scavenging ability in in vitro DPPH assay | [ |
| hepato-protective | up-regulation of phase II and antioxidant enzymes via Nrf2 activation in mice | [ | |
| 3-hydroxyphenylacetic and 3-(4-hydroxyphenyl)propionic acids | anti-inflammatory and anticancer | decrease in the COX-2 levels in colonic HT-29 cells | [ |
| 3- and 4-hydroxyhippuric acid | anti-inflammatory | blockage of prostaglandin E2 production in vitro in CD18-Co human colon fibroblast cells | [ |
| hippuric acid | antimicrobial | bacteriostatic for the common pathogens in the urinary tract | [ |